Skip to content

Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial

Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01453270
Acronym
AGONIST
Enrollment
122
Registered
2011-10-17
Start date
2011-11-30
Completion date
2014-03-31
Last updated
2014-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Shock, Septic

Keywords

Sepsis, Emergency medicine, Cardiac output, Stroke volume, Lactate

Brief summary

The purpose of this study is to determine whether the use of a 3-hour protocol utilizing non-invasive hemodynamic optimization treatment strategy results in better outcome and lower hospital costs in patients who present with severe bloodstream infections to the Emergency Department (ED).

Detailed description

Severe sepsis is a syndrome where the body develops organ dysfunction secondary to uncontrolled inflammatory response to infection. Various resuscitation bundles have been formulated and practised to treat severe sepsis, such as early goal-directed therapy (EGDT). EGDT involves the insertion of invasive catheters in patients with severe sepsis or septic shock using serial measurements to guide therapy and achieve hemodynamic goals, such as mean arterial pressure (MAP), central venous pressure (CVP) and central venous oxygen saturation (ScvO2) by 6 hours. The drawbacks include the invasive nature of inserting these catheters with its complications and tedium to set up the equipment. A non-invasive approach using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg raising (PLR) maneuver to guide fluid and vasoactive agent therapy targeting fluid responsiveness and MAP may be able to achieve better outcome, measured by lactate clearance at 3 hours and at a lower hospitalization cost.

Interventions

DEVICENICOM

Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.

OTHERUsual care

Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.

Sponsors

Singapore Clinical Research Institute
CollaboratorOTHER
National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Fulfillment of at least 2 systemic inflammatory response syndrome (SIRS) criteria * Suspected infection * Serum lactate ≥3mmol/L

Exclusion criteria

* Age below 21 years * Known pregnancy * Prisoners * Do-not-attempt resuscitation status * Known severe aortic insufficiency or severe anatomic abnormalities of the thoracic aorta * Primary diagnosis of trauma, burns, active seizures, acute cerebral vascular accident, acute coronary syndrome, status asthmaticus, major cardiac arrhythmias, active gastrointestinal haemorrhage, seizure or drug overdose * Requirement for immediate surgery * Inability to do PLR (e.g. ankylosis of hip joint, severe sciatica) * Treating physician deems aggressive care unsuitable * Those unable to give informed consent and unable to comply with study requirements

Design outcomes

Primary

MeasureTime frameDescription
Lactate clearance >20%3 hoursArterial lactate levels will be measured at 0 and 3 hours to determine degree of lactate clearance at 3 hours.

Secondary

MeasureTime frame
Total hospital costAt discharge, death or 28 days, whichever occurs earlier

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026